Skip to main content
PTGX
NASDAQ Life Sciences

Protagonist Therapeutics CFO Sells $2.58M in Stock

Analysis by Wiseek AI
Sentiment info
Negative
Importance info
7
Price
$100.11
Mkt Cap
$6.315B
52W Low
$39.6
52W High
$105.69
Market data snapshot near publication time

Summary

Protagonist Therapeutics' Chief Financial Officer, Ali Asif, sold over $2.5 million worth of company stock following an option exercise, continuing a trend of insider sales.


Key Events

  • CFO Sells Shares

    Chief Financial Officer Ali Asif sold 24,765 shares of common stock for approximately $2.58 million at an average price of $104.24 per share.

  • Option Exercise Preceded Sale

    The sale followed the exercise of options to acquire 24,765 shares at strike prices ranging from $12.17 to $19.19, totaling $438,280.

  • Continues Insider Selling Trend

    This transaction adds to a pattern of insider distribution, with over $18 million in net insider sales reported over the last 90 days, including recent Form 144 filings from other executives.


Analysis

This Form 4 filing indicates a significant open market sale by Protagonist Therapeutics' Chief Financial Officer, Ali Asif, totaling approximately $2.58 million. The sale occurred after exercising options. While the percentage of market cap is small for this large company, the absolute dollar value is substantial for an individual executive. This transaction contributes to a broader pattern of insider distribution observed over the past 90 days, with net insider sales exceeding $18 million. Such sales by a key executive can be interpreted by investors as a lack of conviction in the company's near-term stock performance, despite the company's recent clinical pipeline progress mentioned in its last 10-K.

At the time of this filing, PTGX was trading at $100.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $39.60 to $105.69. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PTGX - Latest Insights

PTGX
May 12, 2026, 7:28 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $99.95
Real-time Price: $109.78 info
Change: +$9.83 (+10%) info
Market Cap: $7.06B info
PTGX
May 11, 2026, 8:25 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $103.50
Real-time Price: $109.78 info
Change: +$6.28 (+6%) info
Market Cap: $7.06B info
PTGX
May 05, 2026, 4:28 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $99.21
Real-time Price: $109.78 info
Change: +$10.57 (+11%) info
Market Cap: $7.06B info
PTGX
May 05, 2026, 4:27 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $108.00
Real-time Price: $109.78 info
Change: +$1.78 (+2%) info
Market Cap: $7.06B info
PTGX
May 05, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $99.21
Real-time Price: $109.78 info
Change: +$10.57 (+11%) info
Market Cap: $7.06B info
PTGX
Apr 28, 2026, 4:44 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $101.21
Real-time Price: $109.78 info
Change: +$8.57 (+8%) info
Market Cap: $7.06B info
PTGX
Mar 27, 2026, 7:33 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $100.11
Real-time Price: $109.78 info
Change: +$9.67 (+10%) info
Market Cap: $7.06B info
PTGX
Mar 24, 2026, 5:56 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $100.39
Real-time Price: $109.78 info
Change: +$9.39 (+9%) info
Market Cap: $7.06B info
PTGX
Feb 25, 2026, 4:28 PM EST
Filing Type: 10-K
Importance Score:
7
Price at Filing: $87.10
Real-time Price: $109.78 info
Change: +$22.68 (+26%) info
Market Cap: $7.06B info
PTGX
Feb 25, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $87.10
Real-time Price: $109.78 info
Change: +$22.68 (+26%) info
Market Cap: $7.06B info